Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when REGN files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: REGN REGENERON PHARMACEUTICALS, INC. 8-K

Regeneron grants 10-year performance share units to CEO and CSO, forms new subsidiary with equity stakes

Filed September 30, 2026 · Period ending September 24, 2026 · ~1 min read

5 key changes 4 high relevance 2 sections

Key Changes

  • high

    CEO Leonard Schleifer and CSO George Yancopoulos received one-time performance share unit awards effective September 24, 2026, replacing annual equity awards until 2036.

  • high

    Awards are capped at 2,700,000 PSUs for the CEO and 2,900,000 PSUs for the CSO, with maximum earnout requiring nearly $30 billion in new product annual revenues.

  • high

    No revenue-based PSUs are earned unless new product annual revenues reach at least $10 billion; below that, activity-based earnout is capped at 100,000 PSUs for the CEO and 300,000 PSUs for the CSO.

  • high

    The CEO and CSO agreed not to receive any additional equity or equity-based awards under the Equity Plan until 2036.

    Exhibit 99.1 view on EDGAR →
  • medium

    Regeneron formed a new subsidiary to explore a potential non-core business opportunity, with both executives receiving equity stakes; the subsidiary is majority owned by Regeneron and has nominal value.

Summary

Regeneron Pharmaceuticals granted one-time performance share unit awards to CEO Leonard Schleifer and CSO George Yancopoulos, effective September 24, 2026. The awards replace annual equity grants for both executives until 2036 and are tied to a 10-year performance period ending December 31, 2035.

The PSUs are structured around two operational categories: new product filings and approvals, and new product annual revenues. Revenue-based PSUs only begin to accrue once new product annual revenues reach $10 billion, with maximum earnout requiring nearly $30 billion in new product annual revenues, substantial pipeline advancement, and positive absolute and relative total shareholder return.

The awards are capped at 2.7 million PSUs for the CEO and 2.9 million PSUs for the CSO. The company also formed a new subsidiary to explore a potential non-core business opportunity, with both executives receiving equity stakes. The subsidiary is majority owned and controlled by Regeneron, has nominal value, no significant assets, and has not yet commenced operations. The filing states that the PSU awards were approved after a multi-year process led by the Compensation Committee, incorporating feedback from large investors and independent compensation and governance experts. The design aims to align executive pay with long-term strategic goals, including maximizing the value of the company's pipeline of approximately 50 product candidates amid increasing biosimilar and branded competition.

Section-by-Section Diff

Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation

~1,600 words

Regeneron grants 10-year performance share units to CEO and CSO and forms a new subsidiary with equity stakes for both.

2 Added
Added CEO and CSO performance share unit awards high

Added in current filing · verify on EDGAR →

Effective September 24, 2026 (the “Grant Date”), the Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) granted, upon the approval of the independent, non-employee members of the Board, a one-time award of performance share units (together, the “2026 PSUs”) under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the “Equity Plan”) to each of Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of the Company (“CEO”), and George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of the Company (“CSO”), as described below.

The Board granted one-time performance share unit awards to the CEO and CSO effective September 24, 2026. These awards replace annual equity awards for both executives until 2036 and are tied to a 10-year performance period ending December 31, 2035.

Added Maximum earnout revenue requirement high

Added in current filing · verify on EDGAR →

Maximum earnout requires nearly $30 billion in new product annual revenues, substantial pipeline advancement, positive absolute TSR, and relative TSR outperformance.

To achieve the maximum earnout, the company must generate nearly $30 billion in new product annual revenues, which is approximately double the company's total 2025 revenues. The award also requires substantial pipeline advancement and positive absolute and relative total shareholder return.

Event · Exhibit 99.1

Regeneron discloses terms of 2026 performance share units for its CEO and CSO tied to product filings, approvals, and new-product revenue through 2035.

4 Added
Added 2026 PSU award terms for CEO and CSO medium

Added in current filing · view on EDGAR →

The 2026 PSUs were approved after a rigorous, multi-year process led by the Compensation Committee, incorporating long-term strategic considerations and informed by direct feedback from many of the Company’s largest investors as well as the Compensation Committee’s independent compensation consultant and several other compensation and governance experts.

The filing discloses that the 2026 performance share units (PSUs) for the CEO and CSO were approved after a multi-year process led by the Compensation Committee, with input from large investors and independent compensation and governance experts. The awards are designed to align executive pay with long-term strategic goals, including maximizing the value of the company's pipeline of approximately 50 product candidates amid increasing biosimilar and branded competition.

Added Performance goals for 2026 PSUs high

Added in current filing · view on EDGAR →

10,000 PSUs per New Product Filing from January 1, 20261 through December 31, 2034

The PSUs are tied to two main operational categories: (1) New Product Filings and New Product Approvals, and (2) New Product Annual Revenues. For activity-based PSUs, the CEO and CSO can earn 10,000 PSUs per New Product Filing, 15,000 PSUs per New Product Approval, and 12,500 PSUs per FDA approval of an eligible supplemental filing. Revenue-based PSUs are earned based on New Product Annual Revenues measured in fiscal years 2032-2035, with 250,000 PSUs at $10 billion, 900,000 PSUs at $18 billion, and 1,800,000 PSUs at $30 billion.

Added Maximum earnout opportunities high

Added in current filing · view on EDGAR →

Awards earned pursuant to (1) and (2) above are subject to maximum earnout opportunities of 2,700,000 PSUs (CEO) and 2,900,000 PSUs (CSO)3 that also may be satisfied by the generation of $40 billion of New Product Annual Revenues in fiscal 2034 or 2035 so long as the Company’s absolute TSR is positive for the Performance Period and exceeds the NASDAQ Biotechnology Total Return Index (“NBI”) return over the Performance Period.

The maximum earnout is 2,700,000 PSUs for the CEO and 2,900,000 PSUs for the CSO. The maximum can also be satisfied by generating $40 billion of New Product Annual Revenues in fiscal 2034 or 2035, provided the company's absolute total shareholder return is positive and exceeds the NASDAQ Biotechnology Total Return Index over the performance period.

Added Relative TSR modifier medium

Added in current filing · view on EDGAR →

A relative TSR modifier (“rTSR Modifier”) adjusts earned PSUs by ±20% based on Regeneron’s TSR performance versus the NBI from January 1, 2026 through December 31, 2035 (+20% if Regeneron’s relative TSR exceeds the NBI’s return by 25 percentage points or more and -20% if Regeneron’s relative TSR trails the NBI’s return by 25 percentage points or more, with linear interpolation applied in between)

Earned PSUs are adjusted by plus or minus 20% based on Regeneron's total shareholder return relative to the NASDAQ Biotechnology Total Return Index over the performance period. The modifier cannot increase earned PSUs if Regeneron's absolute TSR is negative over the measurement period.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Oct 3, 2026 · How we verify